BioLine RX Ltd (BLRX) — Cash Flow Reinvestment Rate

Latest as of December 2023: 4.09x

BioLine RX Ltd (BLRX) has a Cash Flow Reinvestment Rate of 4.09x as of December 2023, reinvesting ILA20.41 Million (capex ILA18.00K plus investments ILA-20.39 Million) from operating cash flow of ILA4.99 Million. See cash generation quality of BioLine RX Ltd to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

4.09x

(Capex + Investments) / Operating CF

Total Reinvested

ILA20.41 Million

Capex + Investments

Operating Cash Flow

ILA4.99 Million

ILA

Capital Expenditures

ILA18.00K

ILA

BioLine RX Ltd Cash Flow Reinvestment Rate (2010–2010)

Historical reinvestment intensity for BioLine RX Ltd across 1 annual periods. For the full cash flow conversion analysis, see BLRX cash flow metrics.

Annual Cash Flow Reinvestment Rate for BioLine RX Ltd (2010–2010)

Year-by-year capital reinvestment analysis for BioLine RX Ltd. See BLRX FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.

Year	Reinvestment Rate	Total Reinvested (ILA)	Operating CF	Capex	YoY Change
2010	0.06x	ILA660.94K	ILA11.46 Million	ILA660.94K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow